| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/19/2002 | CA2440555A1 Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| 09/19/2002 | CA2440552A1 Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy |
| 09/19/2002 | CA2440319A1 Tumor radiosensitization and/or chemopotentiation using isocoumarin derivatives |
| 09/19/2002 | CA2440284A1 Ph-dependent nmda receptor antagonists |
| 09/19/2002 | CA2440282A1 Diphenyl derivatives |
| 09/19/2002 | CA2440225A1 Taxane prodrugs |
| 09/19/2002 | CA2440208A1 Tumour targeting prodrugs activated by metallo matrixproteinases |
| 09/19/2002 | CA2440184A1 Heterocyclic derivatives for the treatment of cancer and other proliferative diseases |
| 09/19/2002 | CA2439953A1 Stabilized therapeutic and imaging agents |
| 09/19/2002 | CA2439897A1 Enzyme-activated cytostatic conjugates with integrin ligands |
| 09/19/2002 | CA2439735A1 Igf antagonist peptides |
| 09/19/2002 | CA2439637A1 Human serpin polypeptides |
| 09/19/2002 | CA2439301A1 Compositions comprising matrine and dictamnine for treating or preventing cancer and other diseases |
| 09/19/2002 | CA2438874A1 Fluorinated trienes and their use as rxr modulators |
| 09/19/2002 | CA2438586A1 Retinoid x receptor modulators |
| 09/19/2002 | CA2437958A1 Polymeric immunoglobulin fusion proteins that target low-affinity fc.gamma.receptors |
| 09/19/2002 | CA2437756A1 Nucleic acid-associated proteins |
| 09/19/2002 | CA2433353A1 Crystals of whole antibodies and fragments thereof and methods for making and using them |
| 09/18/2002 | EP1241258A2 Stem cell factor |
| 09/18/2002 | EP1241184A2 Human synaptogyrin-like protein and nucleic acids encoding the same |
| 09/18/2002 | EP1241170A2 Pyrazolopyrimidine derivatives |
| 09/18/2002 | EP1241169A1 Isoindoloindolone derivatives, process for their preparation and pharmaceutical compositions containing them |
| 09/18/2002 | EP1241167A1 3-ethyl-, 3-propyl- or 3-butyl-chroman and -thiochroman derivatives |
| 09/18/2002 | EP1241166A1 3-methyl-chroman and -thiochroman derivatives |
| 09/18/2002 | EP1241165A1 Optically active chroman and thiochroman derivatives |
| 09/18/2002 | EP1240922A2 Methods and compositions for overcoming resistance to biologic and chemotherapy |
| 09/18/2002 | EP1240521A2 Identification of disease markers involving mass-based-separation |
| 09/18/2002 | EP1240352A2 Molecules derived from mechanism based drug design |
| 09/18/2002 | EP1240343A2 Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression |
| 09/18/2002 | EP1240335A2 Proteases |
| 09/18/2002 | EP1240326A2 Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same |
| 09/18/2002 | EP1240323A2 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors |
| 09/18/2002 | EP1240322A2 Therapeutic uses of lna-modified oligonucleotides |
| 09/18/2002 | EP1240317A2 Nucleic acid vaccination |
| 09/18/2002 | EP1240313A2 Homologues of human heparanase and splice variants thereof |
| 09/18/2002 | EP1240309A2 Immature autologous clinical grade dendritic cells intended for vaccination of cancer patients |
| 09/18/2002 | EP1240197A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 09/18/2002 | EP1240196A2 Basolateral sorting signal based on scf peptide and inhibitors thereof |
| 09/18/2002 | EP1240195A2 Polynucleotides and polypeptides encoded thereby |
| 09/18/2002 | EP1240194A2 Novel human protein kinases and protein kinase-like enzymes |
| 09/18/2002 | EP1240190A1 Uses of transport proteins for controlling cell cycle |
| 09/18/2002 | EP1240171A1 Cyclopenteneone derivatives |
| 09/18/2002 | EP1240168A1 Bicyclic inhibitors of glycogen synthase kinase 3 |
| 09/18/2002 | EP1240166A1 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl carboxamide inhibitors of cyclin dependent kinases |
| 09/18/2002 | EP1240165A1 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| 09/18/2002 | EP1240164A1 Benzazole derivatives and their use as jnk modulators |
| 09/18/2002 | EP1240160A1 Substituted pyridazines having cytokine inhibitory activity |
| 09/18/2002 | EP1240159A1 Improved omeprazole process and compositions thereof |
| 09/18/2002 | EP1240158A1 1-(aminophenyl)-2-pyrrolidones as integrin inhibitors |
| 09/18/2002 | EP1240157A2 Substituted n-benzyl-indol-3-yl glyoxylic acid derivatives having an anti-tumoral effect |
| 09/18/2002 | EP1240156A1 3-methyl-chromane or thiochromane derivatives |
| 09/18/2002 | EP1240155A1 Metal salts of 3-methyl-chromane or thiochromane derivatives |
| 09/18/2002 | EP1240153A1 Aminothiazole inhibitors of cyclin dependent kinases |
| 09/18/2002 | EP1240148A1 Benzo[a]phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase i and ii |
| 09/18/2002 | EP1240145A2 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof |
| 09/18/2002 | EP1239887A1 Cobalamin conjugates useful as imaging and therapeutic agents |
| 09/18/2002 | EP1239886A2 Labelled ascorbic acid derivatives |
| 09/18/2002 | EP1239885A1 Interventions to mimic the effects of calorie restriction |
| 09/18/2002 | EP1239881A2 Formulations of adenosine a1 agonists |
| 09/18/2002 | EP1239874A1 Method of diagnosing, monitoring, staging, imaging and treating prostate cancer |
| 09/18/2002 | EP1239871A1 Use of glp-1 agonists for the inhibition of beta cell degeneration |
| 09/18/2002 | EP1239870A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 09/18/2002 | EP1239869A2 Tweak receptor |
| 09/18/2002 | EP1239866A1 INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS |
| 09/18/2002 | EP1239862A2 Pharmaceutical preparation for treating tumor diseases |
| 09/18/2002 | EP1239854A1 Use of a hypoglycemic agent for treating impaired glucose metabolism |
| 09/18/2002 | EP1239845A2 Hydroxide-releasing agents as skin permeation enhancers |
| 09/18/2002 | EP1239829A1 Devices for the delivery of drugs having antiprogestinic properties |
| 09/18/2002 | EP1239826A2 Cosmetic and/or pharmaceutical preparations |
| 09/18/2002 | EP1180113A4 Oligonucleotides having a-dna form and b-dna form conformational geometry |
| 09/18/2002 | EP1117633B1 Diaminocyclobutene-3,4-dione derivatives, their preparation and use |
| 09/18/2002 | EP1104762B1 Substituted imidazo[1,2a]azines as selective inhibitors of cox-2 |
| 09/18/2002 | EP0979239A4 Prevention and treatment of hepatocellular cancer |
| 09/18/2002 | EP0975573B1 Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity |
| 09/18/2002 | EP0934259B1 Beta-sulfonamido hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| 09/18/2002 | EP0921808B1 Non-aqueous polar aprotic peptide formulations |
| 09/18/2002 | EP0904285B1 Cyclic adhesion inhibitors |
| 09/18/2002 | EP0904260B1 Inhibition of matrix metalloproteases by 2-(omega-aroylalkyl)-4-biaryl-oxobutyric acids |
| 09/18/2002 | EP0840604B1 Non-beta-oxidizable fatty acid analogues, their uses as therapeutic active medicaments, and preparation thereof |
| 09/18/2002 | EP0831819B1 Method for inhibiting neoplastic disease in mammals |
| 09/18/2002 | EP0823889B1 1,3-propane diol derivatives as bioactive compounds |
| 09/18/2002 | EP0759765B1 Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression; process of making thereof |
| 09/18/2002 | EP0757681B1 CONDENSED HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE AS GnRH ANTAGONISTS |
| 09/18/2002 | EP0700388B1 Substituted beta-aryl and beta-heteroaryl-alpha-cyanoacrylamide derivatives as tyrosine kinase inhibitors |
| 09/18/2002 | CN1370238A Human poly(ADP-ribose) polymerase 2 materials and methods |
| 09/18/2002 | CN1370232A Methods for making APO-2 ligand using divalent metal ions |
| 09/18/2002 | CN1370231A CASB618 polynucleotides and polypeptides and their use |
| 09/18/2002 | CN1370182A Compounds and methods for therapy and diagnosis of lung cancer |
| 09/18/2002 | CN1370181A Effectors of dipeptidyl peptidase IV for topical use |
| 09/18/2002 | CN1370173A Isomeric fused pyrrolocarbazoles and isoindolones |
| 09/18/2002 | CN1370163A Imidazo [1,2-A] pyridine and pyrazolo [2,3-a] pyridine derivatives |
| 09/18/2002 | CN1370159A Indole derivatives and their use for treatment of osteoporosis amongst other applications |
| 09/18/2002 | CN1370154A Aminothiazole derivatives and their use as CRF receptor ligands |
| 09/18/2002 | CN1370152A 5-cyano-2-aminopyrimidine derivatives |
| 09/18/2002 | CN1370147A Novel integrin alpha V\ beta3 inhibitors |
| 09/18/2002 | CN1370146A Alpha/Beta integrin inhibitors |
| 09/18/2002 | CN1370083A Ninovasive genetic immnization, expression products therefrom, and uses thereof |
| 09/18/2002 | CN1370082A Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| 09/18/2002 | CN1370080A NSAID and EFGR kinase inhibitor contg. compsn. for treatment or inhibition of colonic polyps and colorectal cancer |
| 09/18/2002 | CN1370076A HM 1.24 antigen expression potentiators |